Nasdaq warns Basel Medical (NASDAQ: BMGL) over $1 bid rule breach

Rhea-AI Filing Summary

Basel Medical Group Ltd has received a delinquency notification from Nasdaq because its shares’ closing bid price has been below $1 for the last 30 consecutive business days, violating Nasdaq’s minimum bid price rule for listed securities. The company has a 180 calendar day compliance period, until July 21, 2026, to regain compliance; if its closing bid price is at least $1 for a minimum of ten consecutive business days during this period, Nasdaq will confirm compliance. Basel Medical may also choose to implement a reverse stock split, which must be completed no later than ten business days before the July 21, 2026 deadline to help restore the share price.

If compliance is not regained in this initial period, the company may qualify for an additional 180 calendar days if it meets all other initial listing standards for The Nasdaq Capital Market, except for the bid price requirement, and notifies Nasdaq of its intention to cure the deficiency, potentially via a reverse stock split. If these conditions are not met, Nasdaq may move to delist the shares. Basel Medical states it is working with professional advisers on a rectification plan, and trading of its shares on Nasdaq is currently not affected by the non-compliance.

Positive

• None.

Negative

• Basel Medical received a Nasdaq minimum bid price deficiency notice, creating a defined risk of eventual delisting if it cannot restore its share price to at least $1 for the required period.

Insights

Equity listing and capital markets analyst

Nasdaq’s bid-price warning introduces clear delisting risk for Basel Medical.

Basel Medical Group Ltd has fallen below Nasdaq’s minimum bid price of $1 for 30 consecutive business days, triggering a formal non-compliance notice. This places the company in a defined 180-day remediation window ending on July 21, 2026, during which a sustained closing bid of at least $1 for ten consecutive business days would restore compliance.

The company can also pursue a reverse stock split, which would need to be completed at least ten business days before the July 21, 2026 deadline. Reverse splits often concentrate existing equity into fewer shares at a higher price, but do not change underlying business performance. If Basel Medical fails to regain compliance in the initial period, it may receive a second 180-day period if it meets other Nasdaq Capital Market initial listing standards and formally indicates an intention to cure the deficiency.

If those conditions are not satisfied, Nasdaq may proceed toward delisting, which can reduce trading liquidity and move the shares to a less visible market. The company notes that trading on Nasdaq is currently unaffected and that it is working with professional advisers on a rectification plan, so subsequent disclosures about any proposed reverse split or other actions will frame how this listing risk evolves.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number: 001-42527

Basel Medical Group Ltd

6 Napier Road,

Unit #02-10/11 Gleneagles Medical Centre

Singapore 258499

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Exhibit Index

Exhibit No.		Description
99.1		Press Release – Receipt of Delinquency Notification from Nasdaq

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Basel Medical Group Ltd
	By:	/s/ Darren Yen Feng Chhoa
	Name:	Dr. Darren Yen Feng Chhoa
	Title:	Chief Executive Officer
Date: January 23, 2026

Exhibit 99.1

Receipt of Delinquency Notification from Nasdaq

Singapore, January 23, 2026 (GLOBE NEWSWIRE) — Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), today announced that it has received notification from Nasdaq that based on the closing bid price of the Company’s shares for the last 30 consecutive business days, the Company no longer meets the requirements under Nasdaq’s Listing Rules (the “Rules”) for listed securities to maintain a minimum bid price of $1 per share.

The Rules provide the Company a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180 day period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide you written confirmation of compliance. If the Company chooses to implement a reverse stock split, it must complete the split no later than ten business days prior to the expiration date of July 21, 2026, in order to regain compliance. In the event the Company does not regain compliance, the Company may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that its securities will be subject to delisting.

The Company is currently working with its professional advisers to prepare a rectification plan to remedy the above mentioned non-compliance. Trading of the Company’s shares on Nasdaq is not currently affected by such non-compliance.

About Basel Medical Group Ltd

Basel Medical is a Singapore-based provider of orthopedic and trauma services, sports medicine, orthopedic procedures and surgery, as well as neurosurgical treatments, executive health screening services, occupational medicine, rehabilitation, mental and women’s health and general practices. Our operations are based in Singapore, with our clinics being located at Suntec City Mall, Macpherson Road, Toa Payoh, Margaret Drive, Tampines, Gateway East and Gleneagles Medical Centre. Over the last 20 years, our group has forged strong and lasting relationships with a large base of corporations, in particular those in the construction, marine and oil & gas industries, which underpin our robust business model. As an medical service provider in Singapore with a track record of over 20 years, we are well-positioned to ride the wave of growth opportunities in the private healthcare industry in Singapore and across Southeast Asia driven by ageing populations, rising income levels, increasing private insurance coverage, government effort and expenditure on healthcare, growing sports participation rate and Singapore’s position as a premium destination for healthcare services in Asia. Our management and medical practitioner team comprises a roster of orthopedic and neurosurgery specialists, general practitioners, corporate finance and healthcare partnership specialists. Basel Medical Group Ltd serves as the holding company of our group and we conduct our operations through our operating subsidiaries based in Singapore. For more information, please visit the Company’s website: www.baselmedical.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, which involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

Media Contact:

Basel Medical Group Ltd

+65 6291 9188

contact@baselmedical.com

www.baselmedical.com

FAQ

Why did Basel Medical Group Ltd (BMGL) receive a delinquency notification from Nasdaq?

Basel Medical received the notification because the closing bid price of its shares was below $1 per share for the last 30 consecutive business days, which fails Nasdaq’s minimum bid price requirement for listed securities.

How long does Basel Medical (BMGL) have to regain compliance with Nasdaq’s $1 minimum bid rule?

The company has a 180 calendar day compliance period, ending on July 21, 2026. If its closing bid price is at least $1 for a minimum of ten consecutive business days during this period, Nasdaq will confirm compliance.

What actions can Basel Medical Group Ltd take to regain Nasdaq compliance?

Basel Medical can regain compliance if its shares trade at or above a $1 closing bid for at least ten consecutive business days within the 180-day period. It may also choose to implement a reverse stock split, which must be completed no later than ten business days before the July 21, 2026 deadline.

Can Basel Medical (BMGL) receive additional time beyond the initial 180 days from Nasdaq?

Yes. If the company does not regain compliance in the initial 180 days but meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market (except the bid price), and provides written notice of its intention to cure the deficiency, Nasdaq may grant an additional 180 calendar days.

What happens if Basel Medical still does not meet Nasdaq’s bid price rule after available compliance periods?

If it appears to Nasdaq staff that Basel Medical will not cure the bid price deficiency, or if the company is not eligible for additional time, Nasdaq may notify the company that its securities will be subject to delisting from The Nasdaq Capital Market.

Is trading of Basel Medical Group Ltd’s Nasdaq-listed shares currently affected?

The company states that trading of its shares on Nasdaq is not currently affected by the bid price non-compliance and resulting delinquency notification.

What is Basel Medical Group Ltd doing in response to the Nasdaq notification?

Basel Medical reports that it is working with its professional advisers to prepare a rectification plan to remedy the bid price non-compliance.